Navigation Links
Lenalidomide Gives New Hope To Chronic Lymphocytic Leukemia Patients

According to a phase II study conducted by Asher Chanan-Khan, MD, Department of Medicine, Roswell Park Cancer Institute (RPCI), patients treated with lenalidomide// for relapsed chronic lymphocytic leukemia (CLL) or diseases that no longer responded to chemotherapy have experienced a major response to the therapy. The results of this study were published in the December 1 issue of the Journal of Clinical Oncology.

"Chronic lymphocytic leukemia is the most common hematologic malignancy in the western hemisphere," according to Dr. Chanan-Khan, "and remains incurable." While several phase II studies have demonstrated improved clinical response to chemotherapy alone, or combined with the monoclonal antibody rituximab, relapse is inevitable and treatment options at that point are limited.

Lenalidomide is a novel immune modulating, non-chemotherapy, cancer drug that is chemically similar to thalidomide, but is more potent in the laboratory and appears to lack some of the more common side effects of thalidomide. Anticancer activity of this agent has been reported in various malignant disorders, including multiple myeloma and myelodysplastic syndrome.

In this phase II study – the first to report clinical activity of lenalidomide in patients with CLL – 45 patients with immunophenotypically diagnosed B-CLL were treated with a daily dose of 25 mg of lenalidomide. Major clinical responses were seen in 21 (47%) of the patients, with four achieving complete response and 17 achieving a partial response; all with a predictable and manageable safety profile. The most common side effects included fatigue, neutropenia and thrombocytopenia.

"Collectively, these data provide strong support for further pursuit of lenalidomide in confirmatory clinical studies that are now open at Roswell Park and other cancer centers in the country," notes Dr. Chanan-Khan.



Source-Eurekalert
SR
'"/>




Page: 1

Related medicine news :

1. Lenalidomide, Granted Approval by FDA to Join Multiple Myeloma Drugs
2. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
3. Gene Therapy Gives Hope For Patients With Muscular Dystrophy
4. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
5. US Doctors Association Gives away $110,000 To NGO’
6. Woman In Coma Gives Birth To Daughter
7. Artificial Heart , Gives Hope For Patients Awaiting a Heart Transplant
8. New Eye Surgery Gives Hope To Short-Sighted
9. Jharkhand Gives Health industry status
10. WHO Gives Its Approval For Bird Flu Test Kit
11. FDA Gives Its Approval For Inhaler
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/24/2016)... Lake Orion, Michigan (PRWEB) , ... May 24, 2016 , ... ... Aroma Yoga. , The Yoga practice enhanced with Young Living Essential Oils, taught ... 6:30pm - 8pm at the Lake Orion location. Yoga Flow is 6:30pm - 7:15pm ...
(Date:5/24/2016)... ... ... Controlling and maintaining the home’s water heater just got infinitely easier, more convenient ... , a first-of-its-kind system that enables remote and convenient control of a water heater ... HVAC systems, Aquanta gives users a much more efficient, versatile way to use (or ...
(Date:5/24/2016)... ... May 24, 2016 , ... Aloria Health ... To Begin In June , Aloria Health, specializing in a re-imagined, client-oriented approach ... Aloria Milwaukee, its first treatment facility for outpatient, day treatment and residential care. ...
(Date:5/24/2016)... ... 2016 , ... The old expression “a pain in the neck” takes on ... misunderstood, whiplash should be swiftly diagnosed and treated if those affected want to quickly ... Spine Center . , So named because of the whip-like, rapid back-and-forth neck ...
(Date:5/24/2016)... DC (PRWEB) , ... May 24, 2016 , ... ... month on the successful implementation of protocols designed to reduce bleeding complications from ... Society for Cardiovascular Angiography and Interventions (SCAI) in Orlando, FL, document a 40% ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... 23, 2016 Global Paclitaxel Market ... profiles 12 companies and the Paclitaxel analysis in this ... the industry and its players. This is ... nature, details the current state of the industry while ... classifications, applications and industry chain structure. The Paclitaxel market ...
(Date:5/23/2016)... 23, 2016 According to ... Development, Growth and Demand Forecast to 2022 - ... by Application (Drug Discovery and Development, Proteomics, Clinical ... Life Science and Biotechnology, Academic and Research Institute, ... the global mass spectrometry market was ...
(Date:5/23/2016)... 2016 Non-invasive diagnostic test realizes ... diseases; ,Technology to be presented at Yissum’s booth, at ... Development Company of the Hebrew University of Jerusalem ... with Aurum Ventures MKI, the technology investment arm of ... diagnostic approach for early detection of multiple diseases by ...
Breaking Medicine Technology: